Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma

Abstract RECIST v1.1 has limitations in evaluating progression. We assessed Dynamic Constrast Enhanced Computed Tomography (DCE-CT) identified Blood Volume (BV) for the evaluation of progressive disease (PD) in patients with metastatic renal cell carcinoma (mRCC). BV was quantified prospectively at...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aska Drljevic-Nielsen, Finn Rasmussen, Jill Rachel Mains, Kennet Thorup, Frede Donskov
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7f96e8cb32084215b1cde863c1ebe68b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7f96e8cb32084215b1cde863c1ebe68b
record_format	dspace
spelling	oai:doaj.org-article:7f96e8cb32084215b1cde863c1ebe68b2021-12-02T18:37:11ZBlood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma10.1038/s41598-021-99122-12045-2322https://doaj.org/article/7f96e8cb32084215b1cde863c1ebe68b2021-10-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-99122-1https://doaj.org/toc/2045-2322Abstract RECIST v1.1 has limitations in evaluating progression. We assessed Dynamic Constrast Enhanced Computed Tomography (DCE-CT) identified Blood Volume (BV) for the evaluation of progressive disease (PD) in patients with metastatic renal cell carcinoma (mRCC). BV was quantified prospectively at baseline, after one month, then every three months until PD. Relative changes (ΔBV) were assessed at each timepoint compared with baseline values. The primary endpoint was Time to PD (TTP), the secondary endpoint was Time to the scan prior to PD (PDminus1). Cox proportional hazard models adjusted ΔBV for treatments and International mRCC Database Consortium factors. A total of 62 patients had analyzable scans at the PD timepoint. Median BV was 23.92 mL × 100 g−1 (range 4.40–399.04) at PD and 26.39 mL × 100 g−1 (range 8.70–77.44) at PDminus1. In the final multivariate analysis higher ΔBV was statistically significantly associated with shorter Time to PD, HR 1.11 (95% CI 1.07–1.15, P < 0.001). Also assessed at PDminus1, higher ΔBV was significantly associated with shorter time to PD, HR 1.14 (95% CI 1.01–1.28, P = 0.031). In conclusion, DCE-CT identified BV is a new image-based biomarker of therapy progression in patients with mRCC.Aska Drljevic-NielsenFinn RasmussenJill Rachel MainsKennet ThorupFrede DonskovNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Aska Drljevic-Nielsen Finn Rasmussen Jill Rachel Mains Kennet Thorup Frede Donskov Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
description	Abstract RECIST v1.1 has limitations in evaluating progression. We assessed Dynamic Constrast Enhanced Computed Tomography (DCE-CT) identified Blood Volume (BV) for the evaluation of progressive disease (PD) in patients with metastatic renal cell carcinoma (mRCC). BV was quantified prospectively at baseline, after one month, then every three months until PD. Relative changes (ΔBV) were assessed at each timepoint compared with baseline values. The primary endpoint was Time to PD (TTP), the secondary endpoint was Time to the scan prior to PD (PDminus1). Cox proportional hazard models adjusted ΔBV for treatments and International mRCC Database Consortium factors. A total of 62 patients had analyzable scans at the PD timepoint. Median BV was 23.92 mL × 100 g−1 (range 4.40–399.04) at PD and 26.39 mL × 100 g−1 (range 8.70–77.44) at PDminus1. In the final multivariate analysis higher ΔBV was statistically significantly associated with shorter Time to PD, HR 1.11 (95% CI 1.07–1.15, P < 0.001). Also assessed at PDminus1, higher ΔBV was significantly associated with shorter time to PD, HR 1.14 (95% CI 1.01–1.28, P = 0.031). In conclusion, DCE-CT identified BV is a new image-based biomarker of therapy progression in patients with mRCC.
format	article
author	Aska Drljevic-Nielsen Finn Rasmussen Jill Rachel Mains Kennet Thorup Frede Donskov
author_facet	Aska Drljevic-Nielsen Finn Rasmussen Jill Rachel Mains Kennet Thorup Frede Donskov
author_sort	Aska Drljevic-Nielsen
title	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
title_short	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
title_full	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
title_fullStr	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
title_full_unstemmed	Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
title_sort	blood volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7f96e8cb32084215b1cde863c1ebe68b
work_keys_str_mv	AT askadrljevicnielsen bloodvolumeasanewfunctionalimagebasedbiomarkerofprogressioninmetastaticrenalcellcarcinoma AT finnrasmussen bloodvolumeasanewfunctionalimagebasedbiomarkerofprogressioninmetastaticrenalcellcarcinoma AT jillrachelmains bloodvolumeasanewfunctionalimagebasedbiomarkerofprogressioninmetastaticrenalcellcarcinoma AT kennetthorup bloodvolumeasanewfunctionalimagebasedbiomarkerofprogressioninmetastaticrenalcellcarcinoma AT frededonskov bloodvolumeasanewfunctionalimagebasedbiomarkerofprogressioninmetastaticrenalcellcarcinoma
_version_	1718377806890532864

Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma

Ejemplares similares